Vascular Effects of Sertraline in Heart Failure
Information source: Yale University
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heart Failure; Depression
Intervention: sertraline (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Yale University Official(s) and/or principal investigator(s):
Stuart Katz, MD, Principal Investigator, Affiliation: Yale School of Medicine
Overall contact:
Stuart Katz, MD, Phone: 203-785-7191, Email: stuart.katz@yale.edu
Summary
To determine the effects of chronic sertraline treatment on brachial artery flow-mediated
dilation in patients with chronic heart failure and depression
Clinical Details
Official title: Effects of Chronic Sertraline Hydrochloride Administration on Vascular Endothelial and Autonomic Function in Patients With Chronic Heart Failure
Study design: Cohort, Prospective
Primary outcome: Brachial artery flow-mediated dilation
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chronic heart failure with LVEF<40%, age >21 years
- Depression requiring medical treatment with sertraline
Exclusion Criteria:
- Known intolerance of sertraline
Locations and Contacts
Stuart Katz, MD, Phone: 203-785-7191, Email: stuart.katz@yale.edu
Yale University School of Medicine, New Haven, Connecticut 06510, United States; Recruiting
Stuart Katz, Phone: 203-785-7191, Email: stuart.katz@yale.edu
Stuart Katz, MD, Principal Investigator
Additional Information
Starting date: January 2006
Ending date: December 2008
Last updated: June 12, 2008
|
